Website Notice Block

Press Releases

Date Title and Summary View
Toggle Summary MediWound Initiates Second Phase 2 Clinical Trial of EscharEx(TM) to Treat Chronic and Other Hard-to-Heal Wounds
Trial to Build Upon Earlier Study With Encouraging Outcomes in Poorly Served Multibillion-Dollar Market
View HTML
Toggle Summary MediWound Announces Successful GMP Manufacturing Audit by the Israeli Ministry of Health View HTML
Toggle Summary MediWound Completes Recruitment of Commercial Management Team in Europe
Expanding Commercial and R&D Leadership
View HTML
Toggle Summary MediWound Expands Distribution of NexoBrid to Russia Through Agreement With Genfa Medica View HTML
Toggle Summary MediWound Announces Extraordinary General Meeting of Shareholders View HTML
Toggle Summary MediWound Reports First Quarter 2014 Financial Results View HTML
Toggle Summary MediWound Announces Closing of Initial Public Offering View HTML
Toggle Summary MediWound Prices Initial Public Offering View HTML
Toggle Summary Positive Recommendation for Marketing Authorization from the European Medicines Agency for its innovative drug – NexoBrid™
NexoBrid™ has shown statistically significant effect in earlier eschar removal from burn wounds and reduction in the number and extent of surgical excision and autografting
View HTML